At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
curcumin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IIA Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
In Brief
A Phase 2 clinical trial evaluating laboratory biomarker analysis, pharmacological study, and 1 other intervention for Healthy, no Evidence of Disease and Tobacco Use Disorder. Completed, enrolled 44 participants across 1 site.
Detailed Summary
Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. Curcumin is a compound found in plants that may prevent colon cancer from forming. This phase II trial is studying how well curcumin works in preventing colon cancer in smokers with aberrant crypt foci.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2006
Enrollment StartOct 2006
Primary CompletionSep 2008
Study CompletionJan 2011
TodayJul 2026
First PostedAug 17, 2006
Enrollment StartOct 1, 2006
Primary CompletionSep 1, 2008
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.9 years ago
Interventions
laboratory biomarker analysisother
Correlative studies
pharmacological studyother
Correlative studies
curcumindrug
Given orally